Even granting that this is a challenging time for the orthopedics industry (and healthcare device providers in general), Smith & Nephew (NYSE:SNN) is struggling a little more than most. The company has been losing share in orthopedic implants like hips and knees and disappointing investors with regards to cash flow production, and the stock has been chopping around in a $20 range for about three years now. While the news on November 28 of the company's Healthpoint Biotherapeutics acquisition does bring in advanced wound care products with very good growth, Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term plan.

Guide To Oil And Gas Plays: We've got your comprehensive guide to oil and gas shales in North America.

Buying a Good Product That Most People Haven't Heard of
Wound care is not an especially well-appreciated segment of the healthcare market, so it's altogether understandable if most investors aren't familiar with "bioactive wound healing" or Healthpoint Biotherapeutics. Nevertheless, Smith & Nephew will be paying $782 million in cash to acquire Healthpoint and its portfolio of products build around bioactive debridement, dermal repair and wound regeneration.

The principle asset of Healthpoint is Collagenase Santyl pointment, an enzymatic debrider for dermal ulcers and burns. This product alone makes up about three-quarters of Healthpoint's sales and has been growing quite well for the company. Other products of note include Oasis for leg ulcers and Regranex for diabetic foot ulcers. Healthpoint also had a product in Phase 3 studies (HP802-247) for venous leg ulcers.

Smith & Nephew indicated that Healthpoint was on target for $190 million in sales this year, up about 25% from last year. While the company provided less information on recent margins, it seems as though Healthpoint is not strongly profitable at this point - though due at least in part to a lack of scale.

SEE: Analyzing An Acquisition Announcement

It's Logical to Get Bigger Here
With about 90% of Healthpoint's sales in the United States, this will double the company's U.S. wound care business, and grow the overall wound care business by about 20%. That will elevate wound care to about 30% of the total, so orthopedics will still be a significant part of the story post-deal.

Expanding the wound care business makes plenty of sense for Smith & Nephew. For starters, while Kinetic Concepts and Smith & Nephew have both faced challenging reimbursement decisions in wound care, it's not a market with a significant elective procedure component. What's more, it's also a market still in need of (and willing to pay for) better technology and better outcomes - persistent wounds/ulcers are a major problem for patients with limited mobility, and particularly those with diabetes.

This also happens to be a market where Smith & Nephew has scale and influence. This deal will significantly close the gap with Kinetic Concepts in terms of overall market share, and should give the company a meaningful boost in bioactive wound healing - one of the strongest growth segments in the market. Together, these two companies will have close to 50% share, with 3M (NYSE:MMM) and Convatec a ways back. What's more, this is not an easy buy ((Johnson & Johnson (NYSE:JNJ) largely exited professional wound care in 2008)), but it is one that I believe is still worthwhile and can reward a disciplined player with scale.

It's also worth noting that Smith & Nephew isn't getting anywhere fast in orthopedics. While companies like Johnson & Johnson, Zimmer (NYSE:ZMH) and Stryker (NYSE:SYK) generally saw about a 2% growth in their reconstruction businesses (hips and knees) in the third quarter, Smith & Nephew saw a 2% decline, with particular weakness in hips. Now some of this can be tied to Smith & Nephew's greater exposure to Europe (where reimbursement pressures are more intense), but it can also be tied to the fact that Smith & Nephew's products are longer in the tooth and the company has not been as innovative as its rivals.

SEE: 5 Must-Have Metrics For Value Investors

The Bottom Line
Although I like the Healthpoint deal, paying more than four times sales makes for an expensive deal these days ((though not out of line given what Shire (Nasdaq:SHPG) paid for Advanced BioHealing in 2011)). Healthpoint is a good enough asset to be worth this price, but the point stands that Smith & Nephew needs to step up its R&D/innovation game, as it cannot afford to keep buying growth at this sort of multiple.

Though I think the deal is a good one for Smith & Nephew, it doesn't change my feeling that this is a stock better left out of investors' portfolios. There are too many quality names out there ((like Medtronic (NYSE:MDT) and Covidien (NYSE:COV)) to go with Smith & Nephew instead, and if investors want to take some risk and invest in companies that need to improve their execution, St. Jude (NYSE:STJ) and Stryker look like better candidates for that sort of move.

At the time of writing, Stephen D. Simpson has owned shares of 3M since 2007.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Financial Advisors

    Breaking Down Medicare Open Enrollment for Clients

    For financial advisors, open enrollment is an important opportunity to be of service to clients, especially when it comes to reviewing Medicare options.
  5. Retirement

    Top Signs You Aren’t Ready to Retire Yet

    Think you are prepared to retire? These warning signs may indicate otherwise.
  6. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  7. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  8. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  9. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  10. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  1. Is dental insurance tax deductible?

    Dental insurance premiums may be tax deductible. To be deductible as a qualifying medical expense, the dental insurance must ... Read Full Answer >>
  2. Does a Flexible Spending Account (FSA) cover massages?

    Flexible Spending Accounts (FSAs) cover massages for certain medical treatments. These treatments must be approved and prescribed ... Read Full Answer >>
  3. Do flexible spending accounts (FSA) funds roll over?

    An individual can utilize an employer’s cafeteria plan of employee benefits to establish a flexible spending account (FSA). ... Read Full Answer >>
  4. Does CareCredit cover prescriptions?

    In the United States, the health care sector is one of the fastest growing and costliest industries. The demand placed on ... Read Full Answer >>
  5. What are catch-up contributions for Health Savings Accounts (HSAs)?

    The U.S. Internal Revenue Service (IRS) allows an eligible individual with a Health Savings Accounts (HSA) who turns 55 or ... Read Full Answer >>
  6. Who can make catch-up contributions to a Health Savings Account (HSA)?

    An eligible individual who is 55 years or older at the end of his tax year can make additional catch-up contributions to ... Read Full Answer >>

You May Also Like

Trading Center